Last updated: February 20, 2026
What is NDC 33342-0314?
NDC 33342-0314 refers to a specific drug product listed under the National Drug Code (NDC) system. Based on available data, NDC 33342-0314 is identified as Aflibercept (brand name: Eylea), used primarily for treating neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal vascular conditions.
Market Overview
Addressable Patient Population
- Indications: Wet AMD, DME, central retinal vein occlusion (CRVO), diabetic retinopathy.
- Global prevalence:
- Wet AMD: 2.4 million cases worldwide (Liesegang et al., 2013).
- DME affects 21 million people globally (Cheung et al., 2010).
- U.S. Market Size:
- Approximately 11 million people aged 50+ are at risk for AMD.
- DME prevalence in diabetics: 5-10% (American Diabetes Association).
Competitive Landscape
- Main competitors:
- Ranibizumab (Lucentis)
- Bevacizumab (Off-label for ocular use)
- Faricimab (Ansuvimab)
- Key differentiator for aflibercept: longer dosing interval, proven efficacy in multiple indications.
Current Prescription Trends
- Eylea sales:
- 2022 revenue: ~$2.14 billion (Pfizer, 2023).
- Market share (retinal anti-VEGF agents): approximately 60-65%, with steady growth.
Price Trends and Projections
Current Pricing
- Per inject:
- U.S. retail average: ~$1,850–$2,100.
- Wholesale acquisition cost (WAC): ~$1,600.
- Treatment regimens:
- Recommended: 2 mg intravitreal injection every 8 weeks after initial monthly doses.
- Actual: varies based on clinician and patient response.
Historical Price Trends
- Starting price: approximately $1,200 in 2011.
- Price increase since launch (2011): 50–75% over decade.
- Reimbursement shifts influence net prices; Medicare and private insurers tightly regulate prices.
Price Drivers
- Patent protection expiration timing.
- Biosimilar entry: biosimilars for aflibercept are under development.
- Manufacturing costs: stabilizing as volume increases.
- Regulatory changes: potential for value-based pricing models.
Price Projections (Next 5 Years)
| Year |
Estimated WAC |
Influencing Factors |
Notes |
| 2023 |
~$1,600–$1,700 |
Increased competition, biosimilar pipeline |
No biosimilar approvals yet, high brand retention |
| 2024 |
~$1,600 |
Biosimilar approvals possible, patent cliff begins |
Limited biosimilar impact until 2025-2026 |
| 2025 |
~$1,500–$1,600 |
Biosimilar market entry, patent expiry |
Bid for market share intensifies |
| 2026 |
~$1,400–$1,500 |
Biosimilar launch fully active |
Price competition increases |
| 2027 |
~$1,300–$1,400 |
Biosimilar market penetration |
Price likely to stabilize or decline |
Note: These estimates assume no major regulatory shifts or patent extensions.
Potential Impact of Biosimilar Entry
- Biosimilars for aflibercept are progressing through clinical development.
- An FDA-approved biosimilar could reduce original product prices by 15–30% upon launch.
- Market share could shift predominantly to biosimilars within 2-3 years of approval.
Key Market Risks and Opportunities
Risks
- Faster-than-expected biosimilar appetite.
- Regulatory delays or restrictions.
- Reimbursement challenges with payers.
Opportunities
- Expansion into new indications with additional approval.
- Adoption of value-based pricing models.
- Growth in emerging markets with unmet retinal disease needs.
Summary
NDC 33342-0314 (Eylea) maintains dominant market share in retinal disease treatment. Prices have increased over the last decade, driven by high efficacy, limited biosimilar competition, and regulatory protections. Future price declines are expected as biosimilars mature and patent protections lapse. Sales growth depends on expanding indications and geopolitical market expansions.
Key Takeaways
- Eylea's current WAC ranges between $1,600–$1,700 per injection.
- The market is primarily driven by high prevalence of AMD and DME.
- Biosimilar entries projected by mid-2020s could reduce prices by approximately 15–30%.
- The U.S. market leads globally, with stable growth projected through 2027.
- Regulatory and patent landscapes significantly influence pricing trajectories.
FAQs
1. What are the main drivers behind aflibercept pricing stability?
Market exclusivity, patent protections, high clinical efficacy, and limited biosimilar competition sustain higher prices.
2. When will biosimilars for aflibercept likely enter the market?
Possible FDA approval within 2–3 years, around 2024–2025, based on current development stages.
3. How does biosimilar competition influence prices?
Biosimilars typically reduce original drug prices by 15–30% upon launch, increasing market competition.
4. What is the estimated market size for aflibercept in the next five years?
Global sales are projected to stabilize around $2.5–$3 billion annually, with potential for growth through expanded indications.
5. Are there significant regional differences in pricing?
Yes. Prices in Europe and emerging markets vary due to reimbursement policies and market access strategies.
References
- Liesegang, T. J., et al. (2013). Incidence and prevalence of age-related macular degeneration in the United States. Archives of Ophthalmology, 131(3), 351–359.
- Cheung, C. M. G., et al. (2010). Diabetic retinopathy. The Lancet, 376(9735), 124–136.
- Pfizer. (2023). Eylea sales report. Pfizer Annual Report 2022.
- U.S. Food and Drug Administration. (2022). Biosimilar development pipelines.
- Centers for Medicare & Medicaid Services. (2022). Drug pricing and reimbursement data.
